When Teva Pharmaceuticals Industries made an unsolicitated offer to buy out Mylan for USD 40 billion in cash and stock, it ruffled shareholders of Natco Pharma a little. Natco had teamed up with Mylan to challenge the validity of Teva’s patented 20 mg ...
Money Control · 4/22/2015
or $232.23 per share in cash and Mylan stock. Perrigo disputed the value of those offers, saying they looked richer than they really were because Teva's offers had driven up the price of Mylan shares. Its stock is trading well below Mylan's proposed price.
Modern Healthcare · 7/28/2015
Mylan’s cash-and-stock offer comes at a premium of 24 percent to the latest closing price for Perrigo shares, according to the Associated Press. The combined company will be a juggernaut in generic and specialty drugs as well as over-the-counter …
ETF Trends Setting The Pace · 4/8/2015
Mylan's $34 billion offer for the Irish company depended heavily on the value of its stock, which tumbled 15 percent with the deal from Teva off the table. Mylan shares accounted for about two-thirds of its cash-and-stock offer for Perrigo. “Now that the ...
The shareholders claim that in the run-up to the tax inversion, which was approved by a shareholder vote, Mylan assured investors that the company would remain listed on the Nasdaq stock exchange and abide by …
The American Lawyer · 7/29/2015
Generic drug giant Teva formally offered to buy fellow drugmaker Mylan for about $40.1 billion in cash and stock on Tuesday, despite Mylan's cold shoulder and the certainty the proposed acquisition will bring intense scrutiny by antitrust regulators.
Los Angeles Times · 4/21/2015
In April, Teva proposed to buy Mylan for $82.00 per share, comprising about 50 percent cash and 50 percent stock, valuing the deal at about $40 billion. Teva also said that Mylan would need to back away from its acquisition bid for Perrigo Co plc.
NASDAQ · 7/23/2015
in cash and stock. But Dublin-based Perrigo, which makes over-the-counter medicines, once again rejected the takeover offer. Despite the repeated rejections, Mylan said it looks forward to completing a buyout of Perrigo "in the coming months," according to ...
Medical Xpress · 7/29/2015
Mylan has confirmed it will dual list on the TASE and Nasdaq if it acquires Perrigo. One of the main worries of Tel Aviv Stock Exchange (TASE) leaders recently has been the expected delisting of Perrigo Company (NYSE:PRGO; TASE:PRGO), if and when … · 6/18/2015
The company said it would pay $205 in a combination of cash and Mylan stock for each Perrigo share, which represents a greater than 25% premium to the latter’s stock price as of April 3, 2015. According to Mylan, the marriage of these “highly ...
Pharma Times · 4/8/2015


Mylan N.V. is a global generic and specialty pharmaceuticals company registered in the Netherlands and with operational headquarters …
Mylan N.V. is a global generic and specialty pharmaceuticals company registered in the Netherlands and with operational headquarters in Hatfield, Hertfordshire in the United Kingdom. In 2007, Mylan acquired a controlling interest in India-based Matrix Laboratories Limited, a top producer of active pharmaceutical ingredients for generic drugs, and the generics business of Germany-based Merck KGaA. Through these acquisitions, Mylan has grown from the third-largest generic and pharmaceuticals company in the United States to the second-largest generic and specialty pharmaceuticals company in the world. Mylan now has approximately 30,000 employees, more than 1,000 separate products, and serves customers in more than 150 countries and territories. Mylan has a global manufacturing output of more than 45 billion doses.
Data from: Wikipedia · Freebase